T1	Participants 38 125	zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3:
T2	Participants 300 427	zidovudine (AZT)-treated asymptomatic human immunodeficiency virus (HIV)-infected subjects with 200-500 CD4 cells/mm3 at entry.
T3	Participants 432 480	352 subjects were prestratified by prior AZT use
